The aim of the present study was to formulate pulsatile release film coated tablet of zaltoprofen for the treatment of rheumatoid arthritis. Initially solubility of zaltoprofen was enhanced by formulating self emulsifying fast disintegrating tablet of zaltoprofen. Core fast disintegrating tablet of zaltoprofen was coated with ethyl cellulose and eudragit L100 in various proportions as coating polymer. Ethanol was used as coating solvent and dibutyl phthalate as plasticizer. Film coated tablet with different coating levels were formulated and were evaluated for parameters like lag time, rupture time, in vitro dissolution etc. Amongst the nine different formulations P-4 formulation containing 3:1 ratio of ethyl cellulose and eudragit L100 with 5% coating level gives desired lag time with best drug dissolution profile. Formulated film coated tablet of zaltoprofen can be useful for chronotherapeutic treatment of rheumatoid arthritis.
Cite this article:
Rajan Kalamkar, Shailesh Wadher, Ashish Jain. A Novel Pulsatile Release Film Coated Tablet of Zaltoprofen Loaded SNEDDS. Research Journal of Pharmacy and Technology. 2021; 14(8):4287-0. doi: 10.52711/0974-360X.2021.00745
Rajan Kalamkar, Shailesh Wadher, Ashish Jain. A Novel Pulsatile Release Film Coated Tablet of Zaltoprofen Loaded SNEDDS. Research Journal of Pharmacy and Technology. 2021; 14(8):4287-0. doi: 10.52711/0974-360X.2021.00745 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-51
1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative, Arthritis Rheum. 2010; 62 (9): 2569–2581.
2. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis, Eur. J. Radiol. Eur J Radiol. 1998: 18-24.
3. Crielaard BJ, Lammers T, Schiffelers RM, Storm G. Storm, Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release. 2012; 161(2): 225-234.
4. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis, Am. J. Manage. Care 2012; 18 (13): 295–302.
5. Croff ord LJ: Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy 2013, 15(3): 2.
6. Thakur S, Riyaz B, Patil A, Kaur A, Kapoor B, Mishra V. Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview. Biomed Pharmacother. 2018; 106: 1011-1023.
7. Chatap VK, Maurya AR, Marathe GM, Patil ND. Zaltoprofen- β-CD Inclusion Complex for Solubility Enhancement. Journal of Pharma Sci Tech 2013; 3 (1): 37-42.
8. Baek JS, Lim JH, Kang JS, Shin SC, Jung SH, Cho CW. Enhanced transdermal drug delivery of zaltoprofen using a novel formulation. Int J Pharm. 2013; 453(2): 358-362.
9. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of poorly water soluble LTB4 inhibitors. J. Pharm. Sci. 1998; 87: 164-169.
10. Shaji J, Joshi V. Self- microemulsifying drug delivery system (SMEDDS) for improving bioavailability of hydrophobic drugs and its potential to give sustained release dosage form. Ind. J. Pharm. Educ. 2005; 39(3): 130-135.
11. B. R. Lemmer. The clinical relevance of chronopharmacology in therapeutics. Pharmacological Research. 1996; 33 (2); 107-115.
12. J. R. Reddy, M.V. Jyothsna, T. S.M. Saleem, C.M. S. Chetty. Review on: Pulsatile drug delivery systems. J. Pharm. Sci. & Res. 2009; 1(4); 109-115.
13. S. arora, j. Ali. Pulsatile drug delivery system: an approach for controlled drug delivery. Indian journal of pharmaceutical science. 2006; 68 (3): 295-300.
14. Liberman HA, Lackman L, Shwartz JB. Pharmaceutical dosage forms: Tablet volume 3. 2nd edition. Marcel dekkar inc. 1990.
15. Cole. G, Hogan J, and Aulton M/ Pharmaceutical Coating Technology, Taylor and Francis, UK 20002: 427-436.
16. Sungthongjeena S, Puttipipatkhachorna S, Paeratakulc Q, Dashevskyb A, Bodmeierb R. Development of pulsatile release tablets with swelling and rupturable layers. Journal of Controlled Release 2004; 95: 147– 159.
17. Fan TY, Wei SL, Yan WW, Chen DB, Li J. An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. Journal of Controlled Release. 2001; 77: 245–251.
18. Zhu Y and Zheng L. Development and Mathematical Simulation of Theophylline Pulsatile Release Tablets. Drug Development and Industrial Pharmacy. 2005; 3: 1009–1017.